UNSPSC 51383306: Fenclorac

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H16Cl2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5458S22S8I, chemically known as benzeneacetic acid, alpha,3-dichloro-4-cyclohexyl- but generally known as fenclorac, which bears US NIH Compound Identifier 37494. European Medicines Agency schedules Fenclorac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07552MIG.

UNSPSC 51383306 Fenclorac, a Commodity code, nominally refers to a specific active pharmaceutical ingredient, but recent state and local solicitations under this code reflect procurement of naloxone (a medication used to reverse opioid overdose), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products. State and local governments are using this code to acquire pharmaceutical products and related delivery systems for community health initiatives, pharmacy benefit programs, and multi-jurisdictional cooperative purchasing arrangements. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, covering Minnesota and Oregon).

Recent activity centers in Florida and Texas, with multi-state cooperative purchasing coordination through Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, response deadline July 26, 2023. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposal deadline March 26, 2026 and July 1, 2026 contract effective date; this RFP requires vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), comply with cGMP and Drug Supply Chain Security Act standards, and pay a 3 percent administrative fee on all contract purchases.